Pharmacological management of core and comorbid symptoms in autism-spectrum disorder

Advances in Psychiatric Treatment

Volumn 16, Issue 5, 2010, Pages 349-360

  Elvins, Rachel ^a,b   Green, Jonathan ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; GLUTAMIC ACID; HALOPERIDOL; MEASLES MUMPS RUBELLA VACCINE; MELATONIN; METHYLPHENIDATE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PYRIDOXINE; RISPERIDONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VANCOMYCIN; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; AKATHISIA; ANXIETY DISORDER; APPETITE; APPETITE DISORDER; ATTENTION DISTURBANCE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BLOOD DYSCRASIA; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DEVELOPMENTAL DISORDER; DIAGNOSTIC ACCURACY; DIET; DIZZINESS; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DYSKINESIA; DYSLIPIDEMIA; EDUCATION; ELECTROCARDIOGRAM; ENERGY EXPENDITURE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE DYSREGULATION; HEADACHE; HUMAN; HYPERKINESIA; HYPERTENSION; HYPOTENSION; IMMUNOTHERAPY; INFECTION; INSOMNIA; INSULIN RESISTANCE; IRRITABILITY; LIVER DYSFUNCTION; LIVER TOXICITY; MANIA; MENTAL DEFICIENCY; MOOD DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE COMPULSIVE DISORDER; PANCREATITIS; PLATELET SUPPRESSION; POLYPHARMACY; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; REBOUND HYPERKINESIS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOCIAL DISABILITY; SOCIALIZATION; SOMNOLENCE; STEREOTYPY; SUICIDAL IDEATION; SYMPTOMATOLOGY; TACHYCARDIA; TERATOGENICITY; THOUGHT DISORDER; TIC; TREATMENT RESPONSE; VACCINATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77956305937     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.108.005538     Document Type: Review

References (82)

1. Aman MG, Lam KSL, Van Bourgondien ME (2005) Medication patterns in patients with autism: temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology 15: 116-26.
2. Arnold LE, Aman MG, Cook AM, et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry 45: 1196-205.
3. Autism Genome Project Consortium (2007) Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nature Genetics 39: 319-28.
4. Autism Speaks (2009) Autism Speaks announces results reported for the study of fluoxetine in autism (SOFIA). Autism Speaks (http://www.autismspeaks. org/press/as-announces-sofia-results.php).
5. Baird G, Simonoff E, Pickles A, et al (2006) Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368: 210-5.
6. Baron-Cohen S, Mortimore C, Moriarty J, et al (1999) The prevalence of Gilles de la Tourette's syndrome in children and adolescents with autism. Journal of Child Psychology and Psychiatry 40: 213-8. (Pubitemid 29078365)
7. Belsito KM, Law PA, Kirk KS, et al (2001) Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders 31: 175-81.
8. Broadstock M, Doughty C, Eggleston M (2007) Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism 11: 335-48.
9. Buchsbaum MS, Hollander E, Haznedar MM, et al (2001) Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. International Journal of Neuropsychopharmacology 4: 119-25.
10. Buitelaar JK, van der Gaag RJ, van der Hoeven J (1998a) Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Journal of Clinical Psychiatry 59: 56-9.
11. Buitelaar J, van der Gaag R (1998b) Diagnostic rules for children with PDDNoS and multiple complex developmental disorder. Journal of Child Psychology and Psychiatry 39: 911-9.
12. Carlsson ML (1998) Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. Journal of Neural Transmission 105: 525-35.
13. Chez MG, Aimonovitch M, Buchanan T, et al (2004) Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. Journal of Child Neurology 19: 165-9. (Pubitemid 38559707)
14. Davanzo PA, Belin TR, Widawski MH, et al (1998) Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal on Mental Retardation 102: 427-37.
15. Dunbar F, Kusumakar V, Daneman D, et al (2004) Growth and sexual maturation during long-term treatment with risperidone. American Journal of Psychiatry 161: 918-20.
16. Dykens EM (2000) Annotation: psychopathology in children with intellectual disability. Journal of Child Psychology and Psychiatry and Allied Disciplines 41: 407-17.
17. Erickson CA, Posey DJ, Stigler KA, et al (2007) Pharmacologic treatment of autism and related disorders. Pediatric Annals 36: 575-85.
18. Fankhauser MP, Karumanchi VC, German ML, et al (1992) A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry 53: 77-82.
19. Feldman HM, Kolmen BK, Gonzaga AM (1999) Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry 38: 587-93.
20. Fombonne E (2003) The prevalence of autism. JAMA 289: 87-9.
21. Fombonne E (2005) The changing epidemiology of autism. Journal of Applied Research in Intellectual Disabilities 18: 281-94.
22. Ghaziuddin M, Ghaziuddin N, Greden J (2002) Depression in persons with autism: implications for research and clinical care. Journal of Autism and Developmental Disorders 32: 299-306.
23. Gringras P (2000) Practical paediatric psychopharmacological prescribing in autism: the potential and the pitfalls. Autism 4: 229-47.
24. Harrigan EP, Miceli JJ, Anziano R, et al (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 24: 62-9.
25. Hellings JA, Weckbaugh M, Nickel EJ, et al (2005) A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 15: 682-92.
26. Hollander E, Kaplan A, Cartwright C, et al (2000) Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. Journal of Child Neurology 15: 132-5. (Pubitemid 30139880)
27. Hollander E, Dolgoff Caspar R, Cartwright C, et al (2001) An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry 62: 530-4.
28. Hollander E, Phillips A, Chaplin W, et al (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30: 582-9.
29. Hollander E, Wasserman S, Swanson EN, et al (2006a) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology 16: 541-8.
30. Hollander E, Soorya L, Wasserman S, et al (2006b) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology 9: 209-13. (Pubitemid 43255834)
31. Honda H, Shimizu Y, Rutter M (2005) No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry 46: 572-9.
32. Hutton J, Goode S, Murphy M, et al (2008) New-onset psychiatric disorders in individuals with autism. Autism 12: 373-90.
33. Ing BH, Wright DM, Handen BL, et al (2001) Double blind, placebo controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry 40: 658-65.
34. Jaselskis CA, Cook EH, Fletcher KE, et al (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology 12: 322-7.
35. Jahromi LB, Kasari CL, McCracken JT, et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders 39: 395-404.
36. Jesner OS, Aref-Adib M, Coren E (2007) Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews issue 1: CD005040.
37. Kerbeshian J, Burd L, Fisher W (1987) Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. Journal of Clinical Psychopharmacology 7: 401-5. (Pubitemid 18006087)
38. Kim JA, Szatmari P, Bryson SE, et al (2000) The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. Autism 4: 117-32.
39. King BH, Wright DM, Handen BL, et al (2001) Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry 40: 658-65.
40. King BH, Hollander E, Sikich L, et al (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry 66: 583-90.
41. Lecavalier L, Leone S, Wiltz J (2006) The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. Journal of Intellectual Disability Research 50: 172-83.
42. Lee DO, Ousley OY (2006) Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 16: 737-46.
43. Lord C, Leventhal BL, Cook EH (2001) Quantifying the phenotype in autism spectrum disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 105: 36-8.
44. Luby J, Mrakotsky C, Stalets MM, et al (2006) Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology 16: 575-87.
45. Martin A, Koenig K, Scahill L, et al (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology 9: 99-107. (Pubitemid 29379846)
46. McDougle CJ, Naylor ST, Cohen DJ, et al (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 53: 1001-8.
47. McDougle CJ, Holmes JP, Carlson DC, et al (1998) A double blind placebo controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry 55: 633-41.
48. McDougle CJ, Kresch LE, Posey DJ (2000) Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders 30: 427-35.
49. McDougle CJ, Scahill L, Aman MG, et al (2005) Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry 162: 1142-8.
50. McDougle CJ, Stigler KA, Erickson CA, et al (2006) Pharmacology of autism. Clinical Neuroscience Research 6: 179-88.
51. Mesibov GB, Handlan S (1997) Adolescents and adults with autism. In Handbook of Autism and Pervasive Developmental Disorders (eds DJ Cohen, FR Volkman): 309-22. John Wiley & Sons.
52. Myers SM (2007) The status of pharmacotherapy for autism spectrum disorders. Expert Opinion in Pharmacotherapy 8: 1579-603.
53. National Collaborating Centre for Mental Health (2008) Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults (National Clinical Practice Guideline Number 72). National Institute for Health and Clinical Excellence.
54. National Initiative for Autism: Screening and Assessment (2003) National Autism Plan for Children (NAPC). Plan for the Identification, Assessment, Diagnosis and Access to Early Interventions for Pre-school and Primary School Aged Children with Autism Spectrum Disorders (ASD). National Autistic Society (http://iier.isciii.es/autismo/pdf/aut-napc.pdf).
55. Neiderhofer H, Staffer W, Mair A (2002) Lofexidine in hyperactive and impulsive children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry 41: 1396-7.
56. Nikolov R, Jonker J, Scahill L (2006) Autistic disorder: current psychopharmacological treatments and areas of interest for future developments [Portuguese, English]. Revista Brasileira de Psiquiatria 28 (suppl 1): S39-46.
57. Nye C, Brice A (2005) Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database of Systematic Reviews issue 4: CD003497.
58. Owens JA, Babcock D, Blumer J, et al (2005) The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. Journal of Clinical Sleep Medicine 1: 49-59.
59. Owley T, Walton L, Salt J, et al (2005) An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 44: 343-8.
60. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, et al (2003) Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. Journal of Child and Adolescent Psychopharmacology 13: 83-95. (Pubitemid 36570191)
61. Panksepp J, Lensing P (1991) A synopsis of an open-trial of naltrexone treat ment of autism with four children. Journal of Autism and Developmental Disorders 21: 243-9.
62. Posey DJ, Kem DL, Swiezy NB, et al (2004) A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry 161: 2115-7.
63. Posey DJ, Erickson CA, Stigler KA, et al (2006) The use of selective serotonin reuptake inhibitors in autism and related disorders. Journal of Child and Adolescent Psychopharmacology 16: 181-6.
64. Posey DJ (2008) A double-blind placebo-controlled study of D-cycloserine in children with autistic disorder. In Proceedings of the 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry: Abstract 3.53. AACAP.
65. Quintana H, Birmaher B, Stedge D, et al (1995) Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders 25: 283-94.
66. Remington G, Sloman L, Konstantareas M, et al (2001) Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology 21: 440-4.
67. Research Units on Paediatric Psychopharmacology Autism Network (2005a) Randomised, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry 62: 1266-74.
68. Research Units on Paediatric Psychopharmacology Autism Network (2005b) Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry 162: 1361-9.
69. Sandler RH, Finegold SM, Bolte ER, et al (2000) Short-term benefit from oral vancomycin treatment of regressive-onset autism. Journal of Child Neurology 15: 429-35.
70. Sandler A (2005) Placebo effects in developmental disabilities: implications for research and practice. Mental Retardation and Developmental Disabilities Research Reviews 11: 164-70.
71. Santosh PJ, Baird G, Pityaratstian N, et al (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child: Care, Health and Development 32: 575-83.
72. Scahill L, McCracken JT, McGough J, et al (2002) Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 347: 314-21.
73. Scahill L, Aman MC, McDougle CJ, et al (2006) A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 16: 589-98.
74. Shea S, Turgay A, Carroll A, et al (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114: e634-41.
75. Stigler KA, Desmond LA, Posey DJ, et al (2004) A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 14: 49-56. (Pubitemid 38525953)
76. Stigler KA, Diener JT, Kohn AE, et al (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology 19: 265-74.
77. Sugie Y, Sugie H, Fukuda T, et al (2005) Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism and Developmental Disorders 35: 377-85.
78. Symons FJ, Thompson A, Rodriguez MC (2004) Self injurious behaviour and the efficacy of naltrexone treatment: a quantitative synthesis. Mental Retardation and Developmental Disability Research Review 10: 193-200. (Pubitemid 40095894)
79. Tsakanikos E, Costello H, Holt G, et al (2006) Psychopathology in adults with autism and intellectual disability. Journal of Autism and Developmental Disorders 36: 1123-9.
80. Wisniewski, T, Brimacombe MB, Ming X (2007) Pharmaceutical treatment studies in autism and ADHD: a design based review of study quality. Journal of Pediatric Neurology 5: 189-97.
81. World Health Organization (1994) ICD-10 Classification of Mental and Behavioural Disorders. WHO.
82. Yurgelun-Todd DA, Coyle JT, Gruber SA, et al (2005) Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Research 138: 23-31.